Cambridge Cog Regulatory News (COG)

15th February 2016

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Directorate Change

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets computerised neuropsychological tests including those enabling the early detection of dementia, announces the appointment of Steven Powell as Chief Executive Officer ('CEO'). This confirms the role he accepted in July 2015 when the then CEO, Nick Kerton, took an extended leave of absence from the Company due to a serious medical condition.

With over 25 years of operational and investment experience in the pharmaceutical and life sciences sector, Steven joined the Company as Head of European Operations in 2014. In this position, he was heavily involved in the development and implementation of the current product strategy, which is now starting to establish the Company as the leading provider of point of care cognitive assessments for dementia. Since his appointment to the board as COO and Interim CEO in July 2015, he has driven that strategy forward successfully. As a result, the transition from COO to CEO has been a natural one under the circumstances.

Nick Kerton will remain as a Non-Executive Director continuing to support the Company with his extensive technical and market knowledge.

Non-Executive Chairman at Cambridge Cognition, Michael Lewis commented: "We would like to thank Nick for his significant contribution to the development of Cambridge Cognition and we are delighted that Steven has accepted the permanent role of CEO to continue the excellent work that he has been doing since July last year. I am sure that he will continue to develop our management team, evolve the strategy and take the business on to the next level."

Steven Powell, CEO of Cambridge Cognition, commenting on his new role: "I am delighted that I have the confidence of the board to lead the Company to the next phase of growth by implementing the plans that we have been formulating over the past year."  

Enquiries:

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.